Cingulate Inc. announced on June 16, 2026, that the United States Patent and Trademark Office issued U.S. Patent No. 12,653,791, covering key aspects of CTx-1301's formulation and method of use through December 2042. Cingulate Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and neuropsychiatric disorders.
